CONMED (NYSE:CNMD) Given Neutral Rating at Piper Sandler

CONMED (NYSE:CNMD)‘s stock had its “neutral” rating reiterated by research analysts at Piper Sandler in a report issued on Thursday,Benzinga reports. They currently have a $45.00 price objective on the stock, up from their prior price objective of $39.00. Piper Sandler’s target price would suggest a potential downside of 5.79% from the company’s previous close.

A number of other equities analysts also recently issued reports on CNMD. Wall Street Zen upgraded CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Bank of America reissued an “underperform” rating and issued a $40.00 target price on shares of CONMED in a report on Monday, June 29th. JPMorgan Chase & Co. dropped their target price on CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, April 30th. Needham & Company LLC restated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Finally, BMO Capital Markets started coverage on shares of CONMED in a research report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target for the company. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $41.40.

CONMED Stock Performance

Shares of CNMD traded up $4.55 during mid-day trading on Thursday, hitting $47.77. 530,515 shares of the company traded hands, compared to its average volume of 558,222. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 27.02, a P/E/G ratio of 3.27 and a beta of 0.93. The stock has a 50-day moving average price of $36.89 and a two-hundred day moving average price of $38.39. CONMED has a 1 year low of $31.44 and a 1 year high of $56.63. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.28. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The company had revenue of $343.49 million for the quarter, compared to analysts’ expectations of $337.60 million. During the same quarter last year, the company posted $1.15 earnings per share. The firm’s quarterly revenue was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Equities analysts anticipate that CONMED will post 4.38 earnings per share for the current year.

Institutional Investors Weigh In On CONMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNMD. AQR Capital Management LLC boosted its position in shares of CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after purchasing an additional 2,357 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after buying an additional 800 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in CONMED by 5.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after buying an additional 4,565 shares in the last quarter. Intech Investment Management LLC raised its holdings in CONMED by 34.6% during the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after acquiring an additional 5,780 shares during the period. Finally, Creative Planning purchased a new position in shares of CONMED in the second quarter valued at about $310,000.

Key Stories Impacting CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED reported second-quarter earnings of $1.38 per share, well above the $1.10 analyst consensus and up from $1.15 a year earlier. Revenue of $343.5 million also exceeded estimates of $337.6 million. CONMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS guidance to $4.48-$4.60, above the prior analyst consensus of approximately $4.37. The updated outlook was a major positive catalyst for the stock. CONMED Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management said sales rose 6.0% organically excluding the impact of previously announced strategic exits from certain gastrointestinal product offerings, suggesting healthier underlying demand than the headline revenue growth indicates. CONMED Second-Quarter Results and Guidance

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.